Skip to Main Content

Author Details

Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
2007
75
33
PMIDPaper TitleJournal TitlePublished Year
37972659Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.J Hepatol2024
38060314CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.JCI Insight2024
36871660Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.J Invest Dermatol2023
37821462USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation.Cell Death Dis2023
36820825Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.Cancer Immunol Res2023
34510503The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.Hepatology2022
35810190Multi-modal molecular programs regulate melanoma cell state.Nat Commun2022
35913398Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Cancer Res2022
35257150IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma.Cancer Discov2022
35171660Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.JCO Precis Oncol2022
34304249Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Oncogene2021
33907234High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.Sci Rep2021
34675197Calibration-free NGS quantitation of mutations below 0.01% VAF.Nat Commun2021
34462276Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.Cancer Res2021
34111531Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.J Am Coll Surg2021
33947718Cholangiocarcinoma Risk Factors Open the Floodgates for Gut Microbes and Immunosuppressive Myeloid Cells.Cancer Discov2021
32252259Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells.Int J Mol Sci2020
32096245Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models.Hepatology2020
33328484Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.Sci Rep2020
32747369Same Name, Different Game: EGFR Drives Intrinsic KRAS<sup>G12C</sup> Inhibitor Resistance in Colorectal Cancer.Cancer Discov2020
32923885Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients.JCO Precis Oncol2020
31375515A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors.Clin Cancer Res2019
31386048Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas.Neurooncol Pract2019
29270700Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy.Cancer Metastasis Rev2018
30181170BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.Cancer Discov2018
31058252Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.JCO Precis Oncol2018
30268436A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.Cell Syst2018
30510016Correction: <i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.Cancer Discov2018
29496664<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.Cancer Discov2018
29496665A Preexisting Rare <i>PIK3CA</i><sup>E545K</sup> Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 Signaling.Cancer Discov2018
29409809Crosstalk between the Notch signaling pathway and long non-coding RNAs.Cancer Lett2018
29463860The path to metastatic mouse models of colorectal cancer.Oncogene2018
29625050Oncogenic Signaling Pathways in The Cancer Genome Atlas.Cell2018
29563139Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.Clin Cancer Res2018
28957718Accurate quantification of PGE<sub>2</sub> in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS.J Pharm Biomed Anal2018
28634413Topical Fibronectin Improves Wound Healing of Irradiated Skin.Sci Rep2017
28278349Beyond the BRAF<sup>V</sup><sup>600E</sup> hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.Br J Dermatol2017
28297679Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.Cell Rep2017
28445987Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.Oncotarget2017
28289141Oncogenic <i>Kras</i> drives invasion and maintains metastases in colorectal cancer.Genes Dev2017
28178232Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.Nature2017
28114741Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability.Hepatology2017
29112174miRNAs, Melanoma and Microenvironment: An Intricate Network.Int J Mol Sci2017
28514651Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.Cell Rep2017
28658632Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.Cell Rep2017
26787600Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.Sci Rep2016
28078106Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.J Gastrointest Oncol2016
26645196Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Cancer Discov2016
27658789Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.Curr Treat Options Oncol2016
27301722Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.Cancer Discov2016
  • 1 - 50 of 75

Recommended Authors

Huwate Yeerna
Moores Cancer Center, University of California
Career Start Year 2015
Number of shared co-authors 3
Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 2
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Career Start Year 2012
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 3
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 1
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 46
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 13
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 43
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2005
Number of shared co-authors 3
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 48
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 19
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 21
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 9
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 26
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 47
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 10
Yardena Samuels
Weizmann Institute of Science
Career Start Year 1998
Number of shared co-authors 16
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 17
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 3
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 35
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 13
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 44
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 8
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 32
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 14
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 13

Collaborators

Lynda Chin
Co-authored papers 17
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 13
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Jennifer A Wargo
Co-authored papers 9
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 6
Gao Zhang
Co-authored papers 6
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers 6
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 5
Jeffrey E Gershenwald
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Timothy P Heffernan
Co-authored papers 5
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers 4
Andrew D Cherniack
Dana-Farber Cancer Institute
Co-authored papers 4
Yiling Lu
Co-authored papers 4
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Cameron Brennan
Co-authored papers 4
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Reinhard Dummer
University Hospital Zurich
Co-authored papers 3
Chaoran Cheng
Co-authored papers 3
Rehan Akbani
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Luigi Nezi
Istituto Europeo di Oncologia IRCCS
Co-authored papers 3
Zhi Wei
Co-authored papers 3
Mitchell P Levesque
University Hospital Zurich
Co-authored papers 3
Peter W Laird
Van Andel Institute
Co-authored papers 3
Chandra Sekhar Pedamallu
Broad Institute
Co-authored papers 3
Xingzhi Song
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Andrew E Aplin
Thomas Jefferson University
Co-authored papers 3
Chris Sander
Broad Institute of MIT and Harvard
Co-authored papers 3
Yonghong Xiao
TESARO Inc.
Co-authored papers 3
Release 1.2